**Name of journal: *World Journal of Gastrointestinal Endoscopy***

**ESPS Manuscript NO: 11939**

**Columns: REVIEW**

**Risk of transmission of carbapenem-resistant *Enterobacteriaceae* and related “superbugs” during gastrointestinal endoscopy**

Muscarella LF. Risk of CRE transmissions during GI endoscopy

Lawrence F Muscarella

**Lawrence F Muscarella,** LFM Healthcare Solutions, LLC, Colmar, PA 18915, United States

**Author contributions:** Muscarella LF contributed to this paper.

**Supported by** An educational grant provided by FUJIFILM Medical Systems, U.S.A., Inc., Endoscopy Division (Wayne, NJ; United States)

**Correspondence to:** **Lawrence F Muscarella, PhD, President,** LFM Healthcare Solutions, LLC, PO Box 103, Colmar, PA 18915, United States. larry@lfm-hcs.com

**Telephone:** +1-215-4124088 **Fax:** +1-215-4124088

**Received:** June 13, 2014 **Revised:** August 14, 2014

**Accepted:** September 04, 2014

**Published online:**

**Abstract**

To evaluate the risk of transmission of carbapenem-resistant *Enterobacteriaceae* (CRE) and their related superbugs during gastrointestinal (GI) endoscopy. Reports of outbreaks linked to GI endoscopes contaminated with different types of infectious agents, including CRE and their related superbugs, were reviewed. Published during the past 30 years, both prior to and since CRE’s emergence, these reports were obtained by searching the peer-reviewed medical literature (*via* the United States National Library of Medicine’s “MEDLINE” database); the Food and Drug Administration’s *Manufacturer and User Facility Device Experience* database, or “MAUDE”; and the Internet (*via* Google’s search engine). This review focused on an outbreak of CRE in 2013 following the GI endoscopic procedure known as endoscopic retrograde cholangiopancreatography, or ERCP, performed at “Hospital X” located in the suburbs of Chicago (IL; United States). Part of the largest outbreak of CRE in United States history, the infection and colonization of 10 and 28 of this hospital’s patients, respectively, received considerable media attention and was also investigated by the *Centers for Disease Control and Prevention* (CDC), which published a report about this outbreak in *Morbidity and Mortality Weekly Report (MMWR)*, in 2014. This report, along with the results of an independent inspection of Hospital X’s infection control practices following this CRE outbreak, were also reviewed. While this article focuses primarily on the prevention of transmissions of CRE and their related superbugs in the GI endoscopic setting, some of its discussion and recommendations may also apply to other healthcare settings, to other types of flexible endoscopes, and to other types of transmissible infectious agents. GI endoscopy is a recently identified risk factor for the transmission of CRE and their related superbugs, having been associated with patient morbidity and mortality particularly following ERCP. The CDC reported in *MMWR* that the type of GI endoscope, known as an ERCP endoscope, that Hospital X used to perform ERCP in 2013 on the 38 patients who became infected or colonized with CRE might be particularly challenging to clean and disinfect, because of the complexity of its physicial design. If performed in strict accordance with the endoscope manufacturer’s labeling, supplemented as needed with professional organizations’ published guidelines, however, current practices for reprocessing GI endoscopes, which include high-level disinfection, are reportedly adequate for the prevention of transmission of virtually all types of infectious agents, including CRE and their related superbugs. Several recommendations are provided to prevent CRE transmissions in the healthcare setting. CRE transmissions are not limited to contaminated GI endoscopes and also have been linked to other reusable flexible endoscopic instrumentation, including bronchoscopes and cystoscopes.Contaminated GI endoscopes, particularly those used during ERCP, have been causally linked to outbreaks of CRE and their related superbugs, with associated patient morbidity and mortality. Thorough reprocessing of these complex reusable instruments is necessary to prevent disease transmission and ensure patient safety during GI endoscopy. Enhanced training and monitoring of reprocessing staffers to verify the proper cleaning and brushing of GI endoscopes, especially the area around, behind and near the forceps elevator located at the distal end of the ERCP endoscope, are recommended. If the ERCP endoscope features a narrow and exposed channel that houses a wire connecting the GI endoscope’s control head to this forceps elevator, then this channel’s complete reprocessing, including its flushing with a detergent using a procedure validated for effectiveness, is also emphasized.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Endoscopy; Gastrointestinal; Carbapenem-resistant *Enterobacteriaceae;* Cross infection; Disease outbreaks; Healthcare-associated infections; Risk assessment; Disinfection; Sterilization; Anti-bacterial agents; Bacterial infections; Carbapenems; Beta-lactams

**Core tip:** Gastrointestinal (GI) endoscopy, particularly ERCP, is an emerging risk factor for transmission of carbapenem-resistant *Enterobacteriaceae* (CRE) and their related superbugs, as well as of other certain bacteria and viruses. Several recent reports associate outbreaks of CRE following ERCP, with patient morbidity and mortality. If performed properly, however, current practices for reprocessing GI endoscopes, which include high-level disinfection, are reportedly adequate to prevent disease transmission.Enhancing the quality and safety both of infection control in GI endoscopy departments and of the design of GI endoscopes to facilitate their more thorough cleaning and reprocessing is recommended, as it is reasonable to conclude that these recent outbreaks of CRE causally linked to contaminated GI endoscopes may result in more robust and focused oversight and inspections both of manufacturers by regulatory agencies and of healthcare facilities by healthcare accrediting organizations and state health departments. Along with risk assessments, performing root cause analyses that identify for healthcare professionals the likely causes of CRE outbreaks and the actions required to prevent their recurrence is encouraged.

Muscarella LF. Risk of transmission of carbapenem-resistant *Enterobacteriaceae* and related “superbugs” during gastrointestinal endoscopy. *World J Gastrointest Endosc* 2014; In press

**INTRODUCTION**

Common infection control strategies for the prevention of disease transmission during gastrointestinal (GI) endoscopy are routinely credited for the low reported rate of infections due to a contaminated GI endoscope**[1-5]**. Bacterial and viral outbreaks following GI endoscopy, with associated morbidity and mortality, have been reported (albeit infrequently) during the past 30 years, but the cause of virtually every one of these outbreaks was attributed to one or more infection control breaches – for example, to: (1) an endoscope reprocessing lapse, including the failure to clean the GI endoscope’s instrument channel with a brush; or, the faulty reprocessing of the GI endoscope by an automated endoscope reprocessor, or AER, with a flawed internal design; (2) a damaged or improperly maintained or serviced GI endoscope; or (3) the unsterile administration of an *intravenous* (*iv*) medication**[6-14]**. Cleaning, high-level disinfection, and drying of the GI endoscope, either in strict accordance with the endoscope’s labeling or, alternatively, consistent with any one of a number of recently published endoscope reprocessing guidelines, form the tridental cornerstone of infection control in the GI endoscopic setting.

***An outbreak of CRE at Hospital X near Chicago (IL) in 2013 following GI endoscopy***

Despite GI endoscopy’s low reported infection rate, endoscope reprocessing lapses confirmed in recent years have resulted in an heightened focus on patient safety in the GI endoscopic setting**[15]**. And, with the recent emergence of the “superbug” known as carbapenem-resistant *Enterobacteriaceae*, or “CRE”infection control in this setting has taken on even more urgency and closer examination**[16-31]**. Much of this enhanced scrutiny in the U.S. is a direct consequence of the publication in 2014 of a report by the federal *Centers for Disease Control and Prevention* (CDC) documenting an outbreak of CRE identified the previous year at a hospital located in a suburb of Chicago, IL (United States), known herein as “Hospital X”**[25,31]**. Part of the largest in U.S. history, this outbreak of CRE was investigated by the CDC, which determined that 28 and 10 of Hospital X’s patients had been colonized and infected, respectively, with one strain of CRE. (With colonization, the patient carries or harbors the bacterium without displaying any clinical symptoms of infection or disease. Infection, in contrast, is associated with the patient eliciting clinical symptoms that meet certain criteria. Colonization can, but does not always, result in infection.) According to the CDC, each of these 38 patients was exposed to this superbug while undergoing endoscopic retrograde cholangiopancreatography, or “ERCP”, performed by Hospital X between January and September, 2013. (ERCP is a specialized upper GI endoscopic technique that may be used to diagnose and/or treat certain diseases of the biliary or pancreatic ductal systems.) The CDC reported its findings in the January 3, 2014, issue of *Morbidity and Mortality Weekly Report* (*MMWR*)**[25]**.The Illinois Department of Public Health and the Cook County Department of Public Health, as well as the Food and Drug Administration (FDA)**[25]**,assisted the CDC with this investigation, a testament to the potentially significant impact of this landmark outbreak of CRE on public health, infection control in the GI endoscopic setting, and the regulation of complex reusable medical instrumentation.

Determining it to be a reservoir of the outbreak’s strain of CRE and, therefore, presumably responsible for these 38 patient infections and colonizatons, the CDC reported that “the terminal section (the elevator channel)”**[25]** of a side-viewing duodenoscope, also known as an ERCP endoscope, which Hospital X used to perform ERCP on several of these 38 exposed patients, was microbiologically sampled and found to be contaminated with both the outbreak’s strain of CRE, known as New Delhi metallo-β-lactamase-1 (NDM-1)-producing Escherichia coli, and a second strain of CRE**[25,31]**. Although also cultured from this same ERCP endoscope, however, this second strain, known as Klebsiella pneumoniae carbapenemase (KPC)-producing *K. pneumoniae*, reportedly did not result in the colonization or infection of any of Hospital X’s patients**[25]**.An ERCP endoscope not related to Hospital X’s CRE outbreak is displayed in Figure 1A. Most salient, the CDC reported that this implicated ERCP endoscope remained contaminated with the outbreak’s strain of CRE (*i.e.*, NDM-1-producing E. coli) *despite* this instrument having been first manually cleaned and then high-level disinfected using an AER. The CDC further reported in *MMWR* that it did not identify any obvious breaches in the protocol for reprocessing ERCP endoscopes during its investigation of Hospital X’s CRE outbreak**[25-30]**.

In this outbreak’s aftermath, however, an independent inspection of Hospital X’s infection control practices was performed, and a report published, by The Centers for Medicare and Medicaid Services (CMS)**[31]**,which states that the hospital “failed to reprocess ERCP endoscopes as recommended by the endoscope manufacturer”**[31].** Namely, according to the CMS’s report, the endoscope’s manufacturer asserts that Hospital X did not clean the ERCP endoscope using the recommended or approved type of either brush or detergent**[31]**, notwithstanding the CDC’s failure to identify any obvious endoscope reprocessing errors**[25]**.The CMS’s inspection report provides three additional facts not reported by the CDC in *MMWR*: (1) that Hospital X’s CRE outbreak in 2013 was associated with the use of not one, but three ERCP endoscopes of the same model type (the model of the three implicated ERCP endoscopes linked to Hospital X’s CRE outbreak was a Pentax ED-3490TK); (2) that at least two of Hospital X’s 10 patients infected with the outbreak’s strain of CRE died; and (3) that, in addition to the two strains of CRE that the CDC recovered from one of Hospital X’s contaminated ERCP endoscope (*i.e.,* NDM-1-producing *E. coli* and KPC-producing *K. pneumoniae*), a third strain of CRE – namely, NDM-producing *K. pneumoniae* – reportedly infected at least one of these two patients who expired (*i.e.*, “Patient #10”)**[31]**.Indeed, Hospital X’s CRE outbreak therefore documents a rare instance of patient mortality directly linked to a contaminated GI endoscope. The CDC further reported that the ERCP endoscope’s complex physical design “might pose a particular challenge for cleaning and disinfection”**[25].**ERCP endoscopes feature a forceps elevator, which is displayed in Figure 1B and is used by the physician during ERCP to manipulate and control the direction and fine movements of accessories that are manually inserted and passed through the GI endoscope’s accompanying instrument channel. Figure 1A displays the passage of an accessory through the ERCP endoscope’s instrument channel.

Along with the published findings of the CMS’s inspection of Hospital X**[31]**,the CDC’s contemporaenously published report in *MMWR***[25]** emphasing that GI endoscopy is an important risk factor for CRE infections and colonizations inextricably introduces concern and confusion about the safety of GI endoscopy vis-à-vis superbug transmissions. (To date, reports of infections of CRE and their related superbugs have been limited to ERCP and esophagogastro-duodenoscopy, or “EGD”. While CRE transmissions during colonoscopy would presumably be possible, none has been documented to date.) Implying causality, the CDC also reported that once Hospital X replaced the automated high-level disinfection of its ERCP endoscopes with ethylene oxide gas (EtO) sterilization, however, no new cases of CRE transmissions due to a contaminated ERCP endoscope were identified**[25,29,31]**.Indeed, EtO sterilization is more robust than high-level disinfection performed either manually or using an AER (although EtO sterilization is a more time-consuming and financially burdensome process that is no longer used by many healthcare facilities.) In addition to some other aspects of its CRE outbreak, however, Hospital X’s replacement of automated high-level disinfection, which is a “wet” process requiring that the GI endoscope be subsequently rinsed with (bacteria-free) water following chemical immersion, with EtO sterilization, which conversely is a “dry” low-temperature process that does not use water during any of its stages, to prevent additional infections (or colonizations) of CRE might prompt additional speculation about the safety of GI endoscopy and whether current practices for reprocessing GI endoscopes may not be sufficiently rigorous to prevent transmissions of CRE and other related multidrug-resistant bacteria**[26-30]**.

**OBJECTIVE, SCOPE AND METHODOLOGY**

This may be both the first and most comprehensive article to evaluate the risk of transmission of CRE and their related superbugs during GI endoscopy. (Note: In the context of this article “related superbugs” are related to, but are not, CRE, *per se*. Specfically, they are gram-negative bacteria that are either: (1) resistant to carbapenem antibiotics, although not of the *Enterobacteriaceae* family (and therefore not CRE; NDM-1 carbapenemase-producing *Acinetobacter baumannii* and *KPC-producing P. aeruginosa* are examples); or (2) are a multidrug-resistant member of the *Enterobacteriaceae* family, although at this time remain susceptible to carbapenem antibiotics (*e.g.,* ESBL-producing *K. pneumoniae*). It achieves this objective by providing some background information about *Enterobacteriaceae*, CRE, and beta-lactam antibiotics, which include carbapenems to which, as their name indicates, CRE are resistant; by reviewing the recommendations of federal agencies and professional organizations for reprocessing GI endoscopes; and by reviewing, in detail, the CDC’s report published in *MMWR* and the CMS’s contemporaneously published hospital inspection report, both discussing Hospital X’s CRE outbreak in 2013 causally linked to contaminated ERCP endoscopes**[25,31]**.Other instances of disease transmission during GI endoscopy were also reviewed, including several in the FDA’s “Manufacturer and User Facility Device Experience” database, or “MAUDE,” and in the peer-reviewed medical literature. In addition to outbreaks of CRE and their related superbugs following GI endoscopy, these instances document bacterial (and viral) transmissions via contaminated GI endoscopes reported prior to CRE’s emergence. While this article focuses primarily on the prevention of transmissions of CRE and their related superbugs in the GI endoscopic setting, some of its discussion and recommendations may also apply to other healthcare settings, to other types of flexible endoscopes, and to other types of transmissible infectious agents.

**FINDINGS AND RESULTS**

GI endoscopes, particularly ERCP endoscopes, pose a risk of transmission of CRE and their related superbugs, both in the U.S. and globally. Indeed, patient morbidity and mortality due to GI endoscopes contaminated with these antibiotic-resistant bacteria have been reported**[13,20-22,24,26-33]**.Reports of GI endoscopes transmitting other types of bacteria, too, as well as viruses and other infectious agents, also have been published during the past 30 years. No matter, if performed in strict compliance with the endoscope’s labeling, supplemented as needed with professional organizations’ published guidelines, however, current practices for reprocessing GI endoscopes, which include high-level disinfection (performed either manually or using an AER), are reported to prevent transmissions of virtually every type of infectious agent, including CRE and their related superbugs.This assessment is consistent with the current positions of the *Society for Gastroenterology Nurses and Associates* (SGNA)**[32]**,the *American Society of Gastrointestinal Endoscopy* (ASGE)**[32]**, and the CDC**[30]**, the latter of which reports that EtO sterilization of the GI endoscope does not appear necessary to prevent CRE transmissions (the CDC’s findings published in *MMWR* notwithstanding)**[25]**.

A number of questions that this article raises about CRE, their resistance to antibiotics, and the risk of their transmission during GI endoscopy are listed in Table 1. Several reasons why the recent emergence of CRE, both in the U.S. and globally, is a serious public-health concern are listed in Table 2. And, Table 3 provides a number of recommended practices – for example, to clean GI endoscopes thoroughly – intended to prevent the transmission of CRE via a contaminated GI endoscope. For simplicity, this article’s discussion is divided into two sections: the first focuses on the epidemiology and traits of CRE and their related superbugs, and the second on several outbreaks linked to GI endoscopes contaminated not only with CRE, like Hospital X’s outbreak in 2013, but also with other types of infectious agents, including viruses, *prior* to CRE’s emergence around the turn of this century.

**DISCUSSION**

More than any other recent report of disease transmission during GI endoscopy, Hospital X’s outbreak of NDM-1-producing E. coli in 2013, which resulted in the infection or colonization of 38 patients who underwent ERCP, has placed the risk of CRE transmission during GI endoscopy under a powerful microscope, if not also on a front burner. Causing a new sense of urgency, the CDC’s published report of this hospital’s outbreak of CRE**[25]**, coupled with the contemporaneous findings of a hospital inspection report by the CMS associating this outbreak with three contaminated ERCP endoscopes (of the same model type)**[31]**,have heightened understandable speculation and concern about the safety and quality of GI endoscopy. Moreover, the reporting by CMS that two of Hospital X’s 10 CRE-infected patients died has likely irrevocably changed the landscape of infection control and endoscope reprocessing. As a direct consequence of, first, the CDC having attributed a likely cause of Hospital X’s CRE outbreak (at least in part) to the physical design of the ERCP endoscope (Figure 1A and B); and, second, the CDC’s observation that Hospital X’s replacement of automated high-level disinfection for reprocessing its ERCP endoscopes with EtO sterilization may have stopped this CRE outbreak**[25]**, it is reasonable to presume, too, that the FDA’s regulatory oversight of manufacturers of GI endoscopes and related instrumentation, including AERs, may increase. It may be that Hospital X’s CRE outbreak will also cause healthcare accrediting organizations and state health departments to more closely scrutinize the infection-control and endoscope-reprocessing practices of surveyed GI endoscopy departments.

**PART 1: SUPERBUGS, CARBAPENEMS, AND ACQUIRED ANTIBIOTIC RESISTANCE**

***Carbapenem-resistant Enterobacteriaceae, or “CRE”***

“Superbugs” and “nightmare bacteria” are two monikers often used to describe certain epidemiologically important, multidrug-resistant bacteria, including CRE and other related gram-negative bacteria, that pose at least three threats to public health**[17,34]**. First, these bacteria are resistant to multiple classes of antimicrobial drugs. In fact, some strains of CRE are *pan*-resistant (*i.e.,* resistant to *all* antibiotics). Second, these resistant bacteria can share mobile pieces of genetic material, conferring their antibiotic resistance to other once-susceptible bacteria that are physically nearby and of either the same or a different species or family of bacteria. And, third, the mortality rates of patients infected with these superbugs are relatively high (compared to their antibiotic-*susceptible* bacterial counterparts). For example, CRE infections of the bloodstream are reportedly associated with a mortality rate of as high as 40%-50%**[16,33-35]**,which is significantly higher than those of patients with antibiotic-susceptible infections.

According to the CDC, more than 2 million people are infected with a superbug each year in the United States, and at least 23000 die as a consequence, with the overuse of antibiotics being cited by the CDC as the primary cause of the emergence of CRE and other superbugs**[34]**. (Although not a focus of this article, other well-known organisms also commonly referred to as “superbugs” include vancomycin*-*resistant enterococci (VRE) and methicillin-resistant *staphylococcus aureus* (MRSA), both of which are gram-positive bacteria*.*)As their name betrays, CRE are resistant to carbapenems, which are a class of antimicrobial drugs known as broad-spectrum β-lactam antibiotics. This is a concerning trait, because these “big gun” antibiotics have been used by clinicians as a “last line” of defense, or “last resort,” for treating many types of serious infections caused by multidrug-resistant gram-negative bacteria**[17,34]**. CRE’s resistance to carbapenem antibiotics – specific examples of carbapenems include doripenem, ertapenem and imipenem – significantly limits the number of available treatment options. And the very few antibiotics that remain effective for treating CRE-infected patients are generally undesirable because of their adverse side-effects, which can include nephrotoxicity. These and other reasons discussing why the recent emergence of CRE and their related superbugs is a growing public health concern are summarized in Table 2.

CRE are members of the large *Enterobacteriaceae* family, which both includes more than 70 genera and is the largest collection of medically important gram-negative bacilli. Many of the species of bacteria in this family (whether or not multidrug-resistant) are “enteric” (*i.e.*, they commonly reside in the normal, healthy intestinal flora of humans and other types of animals) and “opportunistic” (*i.e.,* they ordinarily cause disease only in patients with weakened or compromised immune systems). Examples of some of this family’s genera include: *K*lebsiella, *Salmonella,* *Enterobacter,* and *Serratia*. Being non-spore forming (vegetative) bacteria, Enterobacteriaceae are readily destroyed by not only high-level disinfection (and sterilization and other harsh environmental conditions), but also by intermediate-level disinfection, and usually even by low-level disinfection.

The increasing resistance of once-susceptible strains of *Enterobacteriaceae* to carbapenems is relatively recent, with the first documented case of CRE infection occurring in a patient in North Carolina (USA), in 2001**[17]**. Emergent species of CRE include: *K. pneumoniae,* whichis the most commonly encountered species of CRE in the United States; *E. coli;* and *Enterobacter cloacae.* Because CRE can be spread through direct or indirect contact with feces (and other infectious materials), not only (among other practices) is proper hand hygiene necessary to interrupt their transmission in the healthcare setting, but also, as this article found, GI endoscopy is a confirmed risk factor for infections and colonizations of CRE and their related superbugs**[25,31]**. While still relatively low, the incidence of healthcare-associated infections (HAIs) caused by CRE and their related superbugs in acute-care hospitals, both in the United States and globally, has increased significantly during the past decade, posing a growing and serious public health threat (Table 2)**[16,19,25,32]**. According to the CDC, data from one national surveillance system suggest that the proportion of *Enterobacteriaceae* in the United States that have acquired a resistance to carbapenems (*i.e*., CRE) has increased more than 3-fold, from 1.2% in 2001 to 4.2% in 2011**[16]**.

Without effective antimicrobial drugs to treat them, infections of CRE could prove to be as insidious to public health as those caused by HIV 30 years ago, and since. Indeed, in contrast to infections caused by CRE, HIV infection: (1) can be controlled with (anti-viral) drugs (whereas some CRE strains are *pan*-resistant); (2) is not associated with a mortality rate of as high as 50% (whereas the mortality rate of CRE infections of the bloodstream may be as high as 50%); (3) requires only *Standard Precautions* to prevent its spread(whereas *Contact Precautions* may be required to prevent the spread of CRE in the healthcare setting); and (4) is not frequently transmitted from one patient to another due to poor hand hygiene, but rather is generally spread only through exposure to infected blood or other infectious fluids and materials (whereas CRE transmissions can be a consequence of poor hand hygiene). Further, although outbreaks of CRE linked to contaminated GI endoscopes, with associated morbidity and mortality, have been reported and no longer are rare adverse events**[13,20-22,33,36-39].**HIV transmission during GI endoscopy has not been documented.

***Carbapenemases, β-lactam antibiotics, and the β-lactam ring***

As discussed, carbapenems are not an effective treatment for patients infected with CRE. An understanding of one important mechanism that renders CRE and their related superbugs resistant to carbapenems requires some knowledge about the molecular structure of these antimicrobial drugs. Carbapenems are a type of β-lactam antibiotic, and - like that of all β-lactam antibiotics, including cephalosporins, monobactams, and penicillins, the latter of which are the archetype of β-lactam antibiotics - the core molecular structure of carbapenems features a β-lactam ring. The four-membered chemical structure of this ring is displayed in Figure 2. The respective molecular structure of a penicillin and of a carbapenem, each necessarily featuring the characteristic β-lactam ring (Figure 2), is displayed in Figure 3A and B, respectively.

The resistance of *Enterobacteriaceae* to carbapenem antibiotics may be mediated by a number of several different mechanisms, although only one is the focus of this review: through their synthesis (or production) of carbapenemases,which are a type of enzyme, known as a β-lactamase enzyme, that hydrolyzes (*i.e.,* chemically breaks down) the β-lactam ring (Figure 2) of carbapenems (and other β-lactam antibiotics) (Figure 3). (Other mechanisms that confer a bacterium’s resistance to an antibiotic include the active removal of the antibiotic from inside the bacterium’s cell, or through the chemical modification of the bacterium’s target site so that the antibiotic no longer recognizes it). Through this one particular mechanism, *Enterobacteriaceae* that are inherently with, or that have acquired, the genetic material (*i.e.*, DNA) necessary to produce carbapenemases can (but do not always) display a resistance to carbapenems, generally precluding the use of these antibiotics to treat infected patients. These resistant bacteria are a specific type of CRE known as carbapenemase-producing Enterobacteriaceae, or “CPE,” which are responsible for most CRE-related outbreaks encountered in the clinical setting, including Hospital X’s aforementioned CRE outbreak**[25]**.(While CPE are a type of CRE, not all CRE are CPE; mechanisms other than the resistant bacteria’s production of carbapenemases can cause CRE to be resistant to carbapenems).

***Extended-spectrum β-lactamase enzymes***

Until recently, bacteria in the *Enterobacteriaceae* family rarely carried the genetic material necessary to synthesize carbapenemase enzymes. As a result, carbapenems were usually an effective treatment for patients infected with these (carbapenem-susceptible) bacteria, including challenging *Enterobacteriaceae* that produce another type of enzyme called extended-spectrum β-lactamases, or “extended-spectrum β-lactamases (ESBLs)”. Indeed, carbapenem antibiotics remain indicated for the treatment of serious infections caused by ESBL-producing *Enterobacteriaceae* (but not those caused by CRE). Reportedly in response to the overuse of antibiotics**[34]**, however, while some strains of *Enterobacteriaceae* remain susceptible to carbapenems, others have acquired the genetic material necessary to produce carbapenemases through the process of natural selection, heralding CPE’s recent emergence. (In this context “n**atural selection” is defined as a process** by which surviving and multiplying bacteria have adapted to their environment. In contrast, those bacteria that do not adapt to their changing environmental conditions generally become extinct. Further, antibiotics can present a “selective pressure” that destroys susceptible, unadapting bacteria, but that, for those bacteria that undergo natural selection and become resistant to the antibiotics, has little or no effect).

Carbapenems were ironically developed a generation ago to treat patients infected with those strains of *Enterobacteriaceae* that had begun to display a resistance to cephalosporins, which previously had been an effective antibiotic treatment for patients infected with these bacteria. This displayed resistance to cephalosporins was predominantly due to these bacteria’s production of ESBLs. Like carbapenemases, ESBLs chemically hydrolyze (*i.e.,* break down and inactivate) the β-lactam ring of cephalosporins, rendering these antibiotics ineffective. ESBL enzymes are distinct from carbapenemase enzymes, however, and while ESBL-producing *Enterobacteriaceae* are resistant not only to cephalosporins but also to most other types of β-lactam antibiotics, including penicillins, they (unlike CRE) currently remain susceptible to carbapenems.

**Carbapenemase-producing Enterobacteriaceae, or CPE**

CPE produce several different types of carbapenemase enzymes, three of which this article discusses.

**KPC-producing *Enterobacteriaceae*:** The most commonly identified carbapenemase in the United States. produced by certain CRE (namely, CPE) is *K. pneumoniae* carbapenemase (or KPC). Isolated for the first time in North Carolina (United States), in 2001, from a patient infected with a carbapenem-resistant strain of K. pneumoniae, KPC has since spread around the world. Logically, strains of *K. pneumoniae* that produce KPC are called KPC-producing *K. pneumoniae*, and, although it reportedly did not infect or colonize any of Hospital X’s 38 affected patients, the CDC recovered this specific type of CRE from the implicated ERCP endoscope during its investigation of Hospital X’s CRE outbreak in 2013**[25]**. Encoded by a highly transmissible gene known as the “*bla*KPC” gene, the KPC enzyme is no longer exclusively produced by *K. pneumoniae*, however. (“*bla*” refers to the gene that is responsible for the bacterium’s production of the said β-lactamase enzyme and, therefore, for the bacterium’s antibiotic resistance. For example, “*bla*KPC” refers to the gene (often, but not always, of *K. pneumoniae*) that is responsible for the production of the subscript-noted enzyme – in this example, of the KPC enzyme.) Due to the concerning ability of CRE (and other superbugs) to share genetic material that confers antibiotic resistance, KPC (although first identified in and still predominantly produced by *K.* pneumoniae) has also been recently identified in other genera and families of gram-negative bacteria that have acquired the *bla*KPC gene – for example, in *E. coil*, *Pseudomonas aeruginosa,* and *Acinetobacter* spp. (*i.e.*,KPC-producing E. coli, KPC-producing P. aeruginosa, and KPC-producing *Acinetobacter* spp., respectively, the latter two of which are not *Enterobacteriaceae*). (Note: *P. aeruginosa*, like *Klebsiella* spp. and *E. coli,* is a gram-negative (non-spore-forming vegetative) bacterium. But, unlike these other two, which are members of the *Enterobacteriacae* family, *P. aeruginosa* is of the *Pseudomonadaceae* family and therefore, while some of its strains may be classified as *bona fide* “superbugs,” it is not a CRE. Similarly, *Acinetobacter* spp. are of the *Moraxellaceae* family, and those bacteria within this family that have acquired the *bla*KPC gene and are resistant to carbapenems are not CRE, although, too, may be classified as superbugs.)

**NDM-producing *Enterobacteriaceae*:** Described first in 2009 in a European patient infected with an antibiotic-resistant bacterium while traveling to India, the NDM-1 (New Delhi metallo-β-lactamase-1) enzyme is a second example of a carbapenemase**[18]**.(The number “1” associated with the initials “NDM” denotes the specificity to the NDM enzyme. NDM-2 and NDM-3, for example, are variants of NDM-1 and therefore are similar, but different, metallo-β-lactamase (MBL) enzymes, featuring unique amino acid substitutions compared to the NDM-1 enzyme and to one another). This infected patient was unsuccessfully treated while in a New Delhi hospital, and, after the patient's repatriation to Europe, a carbapenem-resistant strain of *K. pneumoniae* bearing (*not* the *bla*KPC gene, but the) the *bla*NDM-1 gene was identified as the infection’s cause.(In this section’s example, *bla*NDM-1 refers to the gene of the *K. pneumoniae* bacterium that is responsible for its production of the NDM-1 enzyme.) NDM-1 is referred to as a metallo-β-lactamase (MBL) enzyme because it uses a metal ion (*i.e.*, zinc) to catalyze the hydrolysis of (that is, to chemically inactivate) carbapenems and other β-lactam antibiotics. In addition to identifying the newly described resistance mechanism of NDM-1 for the first time in the United States, a report in 2010 described, also for the first time in the United States, MLB-producing *Enterobacteriaceae***[19]**. NDM-1 was isolated for the first time from a (carbapenem-resistant) strain of P. aeruginosa (which is of the *Pseudomonadaceae* family and therefore, while a superbug, it is not CRE) in Serbia**[40]**, in 2011, and in the United States (Delaware)**[41]**, in 2014.

The most common CRE that produce the NDM-1 enzyme include NDM-1–producing *K. pneumoniae*, the resistance of which is conferred by the *bla*NDM-1 gene; and NDM-1–producing *Enterobacter cloacae* (the resistance of which is also conferred by the *bla*NDM-1 gene). As previously discussed, NDM-1–producing *E. coli* was the specific bacterial strain that the CDC determined in 2013 was responsible for the outbreak of CRE at Hospital X following ERCP**[25,28]**.While not of the *Enterobacteriaceae* family and therefore not CRE, carbapenem-resistant strains of *Acinetobacter* spp. (*i.e.*, *Acinetobacter baumannii*),in addition to producing KPC (*via* the acquired *bla*KPC gene), have also been found in the clinical setting to produce NDM-1 (*via* the acquired *bla*NDM-1 gene) and NDM-2 (*via* the acquired *bla*NDM-2 gene).

**VIM-producing *Enterobacteriaceae*:** First identified in Italy, Verona integron-encoded metallo-β-lactamase, or “VIM,” is a third example of a carbapenemase enzyme produced by certain carbapenem-resistant bacteria (*i.e.,* CPE). This enzyme was initially isolated from P. aeruginosa (which, again, is not a CRE), with a variant of this enzyme (*i.e.*, VIM-1) being isolated from Enterobacteriaceae, namely from VIM-producing *K. pneumoniae* (or VPKP), in the United States in 2010**[42]**. Similar to the KPC enzyme’s production being encoding by the transmissible “*bla*KPC” gene, production of the VIM enzyme is encoded by the *bla*VIM gene. The production of KPC and VIM by strains of CRE confers their resistance (through hydrolysis) to carbapenems.

***CRE’s acquired resistance to carbapenem antibiotics***

In general, bacteria may acquire the genes necessary to become resistant to an antibiotic drug by one of a number of different mechanisms – for instance, through a naturally inherited genetic trait. Virtually all bacteria in the *Enterobacteriaceae* family naturally produce certain β-lactamase enzymes that confer their intrinsic resistance to penicillins (but not carbapenems). Another example is through a spontaneous mutation of their existing genetic material, with the newly acquired resistance-conferring trait being passed on to subsequent generations (*e.g.*, natural selection). (The overuse of antibiotics is a type of “selective pressure” that reportedly has caused bacteria, through natural selection, to acquire the necessary genetic material to synthesize enzymes, such as carbapenemases and ESBLs, that inactivate and render ineffective one or more types of antibiotics, such as carbapenems and cephalosporins, respectively). And a third mechanism by which bacteria may acquire the genes necessary to become resistant to an antibiotic drug is through the acquisition of new genetic material from other, already-resistant bacteria of either the same or of a different bacterial species (or family), with this newly acquired resistance-conferring genetic material being passed on to subsequent generations. An example of this type of “gene sharing” is the horizontal transfer of the blaKPC gene from carbapenemase-producing *K. pneumoniae* to carbapenem-susceptible *E. coli*, resulting in the latter becoming KPC-producing *E. coli*.

***Risk factors for CRE infection***

Independent factors that increase a patient’s risk of becoming infected with CRE include: (1) prior treatment with carbapenems or another antibiotic (*e.g.*, fluoroquinolones and broad-spectrum cephalosporins); (2) receiving treatment in an intensive care unit (ICU); (3) having received mechanical ventilation; (4) being elderly; (5) being immuno-suppressed (*e.g.*, patients receiving an organ or stem cell transplant); (6) the placement of a central venous catheter; and (7) having diabetes. Undergoing GI endoscopy, especially ERCP, also has been recently identified as a risk factor for CRE infection**[25-31,33]**. Notably, Hospital X’s outbreak in 2013 appears to be the first reported instance in the U.S. directly linking GI endoscopes contaminated with CRE to patient morbidity and mortality**[31]**.To date, only patients receiving medical treatment in hospitals (*i.e*., HAIs), long-term acute care facilities, and nursing homes are reportedly prone to CRE infection. According to the CDC, however, *Enterobacteriaceae* that are resistant to carbapenems (*i.e.*, CRE) will soon also be responsible for infections in community settings**[34]**.

***Types of CRE infections, treatment options***

In addition to biliary tract infections and other type of infections associated with contaminated GI endoscopes**[25]**, CRE can cause urinary tract infections (or UTIs, which are the most common types of CRE infections); wound infections; bloodstream infections (which, as previously noted, even with treatment are associated with a 40%-50% mortality rate); and ventilator-associated pneumonia. While very few antibiotics are effective for treating patients infected with CRE, drug treatment may include the administration of polymyxins. These are an older type of antibiotic drug that includes colistin, and, while effective against most gram-negative bacilli and some strains of CRE, polymyxins can have toxic side-effects. Tigecycline may also be used to treat certain CRE infections, but this antibiotic drug achieves poor serum levels, limiting its clinical effectiveness and, therefore, use.

**PART 2: GI ENDOSCOPY**

Although the risk of disease transmission during GI endoscopy is reported to be low, infections and outbreaks due to contaminated GI endoscopes, with associated patient morbidity and mortality, have been documented during the past 30 years, both prior to and since CRE’s emergence**[2,4-12,14,33,34]**. These cases include infections of bacteria, including *P. aeruginosa*, and viruses, namely, the hepatitis B (HBV) or C virus (HCV). Like their emergence in the U.S. and globally, only during the past few years has the transmission of CRE been linked to GI endoscopy**[13,20-22,25,33,36-39].** While for historical purposes, contextual insight, and important perspectives a number of cases of disease transmission during GI endoscopy prior to CRE’s emergence are discussed below, this section’s primary focus in placed on outbreaks of CRE and their related superbugs due to a contaminated GI endoscope.

***Types of infectious agents transmitted during GI endoscopy prior to CRE’s emergence***

Prior to the turn of this century and CRE’s emergence, infections and outbreaks due to contaminated GI endoscopes (while infrequent) had been reported, most often being attributed to the transmission of *P. aeruginosa* during ERCP, and less commonly to the transmission of other types of bacteria including *Enterobacteriaceae* (*e.g.*, *Salmonella* spp., *Klebsiella* spp. and *Serratia* spp.) during either esophagogastroduodenoscopy (or, “EGD”) or colonoscopy**[33]**. (Prior to 2001 the resistance of these transmitted strains of *Enterobacteriaceae* to carbapenems in the United States. and globally was rare). The specific breach typically responsible for these instances of disease transmission was reported to be, as much if not more so than faulty cleaning and inadequate high-level disinfection, improper drying of one or more of the GI endoscope’s several internal channels, particularly the exposed elevator wire channel of some models of ERCP endoscopes, using either manual reprocessing procedures or an AER**[7-9,11,12,14]**. In only a very few cases has the transmission of a bloodborne virus (*i.e.*, HBV or HCV) been reported during GI endoscopy, with the un-sterile administration of an IV medication typically being identified as, or suspected of being, the outbreak’s proximate cause or a likely contributing factor**[9,10]**.And, no cases of the transmission of HIV due to a contaminated GI endoscope have been reported, either prior to or since CRE’s emergence.Providing some crucial insight and conclusions about the corrective actions necessary to prevent the transmission of superbugs during GI endoscopy in later years, the circumstances of several outbreaks reported prior to CRE’s emergence are discussed below. Whether the actual risk of infection via a contaminated GI endoscope is significantly higher than reported (*e.g.*, 1 in 1.8 million), due to under-reporting, the lacking surveillance of post-endoscopic infections, and “missed” infections, has been suggested and is suspected**[33,43]**.

***Specific instances of disease transmission during GI endoscopy prior to CRE’s emergence***

With historical and clinical significance, several instances of disease transmissions during GI endoscopy were reported prior to the emergence of CRE. For example, Birnie *et al***[9]** (1983) report a case of patient-to-patient transmission of HBV during GI endoscopy. This report concludes that the failure to clean, high-level disinfect, and dry the air/water channels of a gastroscope was likely the cause of HBV transmission. While recommending that these channels be thoroughly high-level disinfected to prevent infection, Birnie *et al***[9]** (1983) also suggest consideration of EtO gas (in lieu of high-level disinfection) to sterilize GI endoscopes potentially contaminated with HBV. (The replacement of high-level disinfection with EtO sterilization was the same measure that Hospital X implemented in 2013 to stop its CRE outbreak**[25-31]**). Similarly, Bronowicki *et al***[10]** (1997) report transmission of the HCV from one patient to two others during colonoscopy. These authors conclude that inadequate cleaning of the colonoscope’s working (or instrument) channel; inadequate disinfection of the colonoscope (a 5-min immersion in 2% glutaraldehyde instead of a 20-min immersion as guidelines universally recommend); and the failure to sterilize the reusable biopsy forceps were likely responsible for this outbreak. This report notes, however, the possibility that the improper, un-sterile administration of IV medications was the cause of HBV transmission.

Cryan *et al***[11]** (1984) report an outbreak of *P. aeruginosa* following ERCP, with associated patient morbidity and mortality. This report concludes that this outbreak was related to inadequate high-level disinfection of the ERCP endoscope’s air/water channels. Following the introduction of a modified reprocessing technique, which involved rinsing the ERCP endoscope’s air/water channels with a disinfectant, no further *P. aeruginosa* infections were identified. Allen *et al***[7]** (1987) also report an outbreak of *P. aeruginosa* following ERCP. These authors conclude that this outbreak was due, in part, to the failure by an AER to dry every one of an ERCP endoscope’s internal channels, including its exposed elevator wire channel. According to this report, another contributing factor to disease transmission was likely the contamination of the internal structures and components of the AER used to reprocess the ERCP endoscopes. The outbreak ended only once 70% alcohol was manually suctioned through the ERCP endoscope’s channels followed by their being dried.

Similarly, Alvarado *et al***[8]** (1991) document an outbreak of *P. aeruginosa* following upper GI endoscopy, including ERCP, due to the faulty design of an AER, which resulted in the contamination of the water used by the AER to rinse the GI endoscopes after high-level disinfection. According to these authors, this outbreak, like the outbreak reported by Allen *et al***[7]** (1987), was terminated only once the GI endoscopes, disinfected using the faulty AER, were terminally rinsed with 70% alcohol followed by forced air drying**[8]**.And, Streulens et al. (1993) report an outbreak of *P. aeruginosa* and of three strains of *Enterobacteriaceae* (namely, *K. pneumoniae*, *Enterobacter cloacae,* and *Serratia marcescens*)following ERCP**[12]**. These different bacteria were isolated from the GI endoscope and/or the AER used for reprocessing. Improper reprocessing and drying of the ERCP endoscopes were reportedly at fault. These authors report that the outbreak was terminated once: the ERCP endoscope’s (exposed) elevator-wire channel was properly high-level disinfected; all of the ERCP endoscope’s channels were flushed with 70% alcohol and air dried; and the AER’s internal components were themselves disinfected**[12]**.

In summary, infections and outbreaks due to contaminated GI endoscopes prior to CRE’s emergence were typically caused by *P. aeruginosa* (likely of an exogenous origin) infecting patients during ERCP. Less frequently reported were patient-to-patient transmissions of HBV and HCV. Whereas improper reprocessing, in general, and inadequate drying of the ERCP endoscope’s exposed elevator wire channel, in particular (whether performed manually or using an AER), were often reported to be responsible for bacterial infections following GI endoscopy, viral transmissions, in contrast, were (and are today) often reported to be due to either the improper cleaning of the GI endoscope (or endoscopic accessory) or, possibly more often, to the un-sterile administration of an IV medication during GI endoscopy.

***Transmission of CRE and related superbugs during GI endoscopy***

Like the aforementioned report published in *MMWR* discussing the CDC’s investigation of Hospital X’s CRE outbreak[**25-31]**, a number of other reports published in the medical literature since CRE’s emergence similarly document infections and colonizations of CRE and their related superbugs due to a contaminated GI endoscope, most often (as prior to CRE’s emergence, too) to an ERCP endoscope**[13,20-22,24,33,36-39]**. (The ERCP endoscope's unique and complex physical design - coupled with the increased invasiveness of, and complication rate associated with, ERCP especially in the presence of biliary tract obstruction and tissue injury – may explain why bacterial infections including those caused by CRE are more often associated with ERCP than with any other type of GI endoscopic procedure [Figures 1A and B][7,11,20-22,25]). Providing crucial insight into both the causes and prevention of CRE transmissions during GI endoscopy, several of these recently published reports conclude that the ERCP endoscope’s physical design likely contributed to the transmission of CRE or a related superbug[13,20-22,24-30].

For example, Carbonne *et al***[22]** (2010) discuss a multi-hospital outbreak of CRE identified in a suburb south of Paris, France, in 2009, with 8 documented cases of infection or colonization due to KPC-producing *K. pneumoniae*, following ERCP. According to this report, this outbreak highlights the risk of transmissions of CRE and related multidrug-resistant bacteria during GI endoscopy, particularly during ERCP. Carbonne *et al***[22]** (2010) conclude that a single ERCP endoscope was a “persistent source” of contamination and the mode of transmission of the outbreak’s CRE strain. Publishing findings similar to these authors, Alrabaa *et al***[20]** (2013) reported that, between June, 2008, and January, 2009, 7 patients in Florida (United States) were infected or colonized with KPC-producing *K. pneumoniae* following ERCP performed at one endoscopy center (shared by two hospitals).Whether this report documents the first instance of CRE transmission in the United States *via* a contaminated GI endoscope is unclear. Infection sites included blood, bile, and urine, and one of the infected patients died during hospitalization.

Consistent with both the CDC’s report discussing Hospital X’s CRE outbreak**[25]** and Carbonne *et al***[22]**’s (2010) report, both of which implicate the ERCP endoscope’s complex physical design as likely responsible for disease transmission, Alrabaa *et al***[20]** (2013) found the suspect GI endoscope's “elevator area” to be contaminated with carbapenemase-producing *E. coli* (not the outbreak’s strain of KPC-producing *K. pneumoniae*), due to “inadequate cleaning of the complex terminal part of the ERCP scope.” Acknowledging that the ERCP endoscope is particularly difficult to clean because its distal tip features a “small tube with a complex design including a small mobile metal piece called the ‘elevator’”, Alrabaa *et al***[20]** (2013) conclude that the contaminated GI endoscope itself was the source of this outbreak's CRE strain. According to this report, the ERCP endoscope’s “elevator piece” was not cleaned in accordance with the manufacturers’ instructions and “needs additional manual cleaning using a brush prior to standard scope processing,” to prevent disease transmission and ensure that this elevator piece does not harbor “dangerous microorganisms” or “biodebris” that Alrabaa *et al***[20]** (2013) found remained under the elevator piece of the implicated scope after it was presumably cleaned.

Discussing another outbreak in Clermont-Ferrand, France, Aumeran *et al***[21]** (2010) report that 16 patients were infected or colonized with an ESBL-producing K. pneumoniae following ERCP performed between December, 2008 and August, 2009(As previously discussed, whereas CRE are resistant to both types of antibiotics, ESBL-producing *Enterobacteriaceae* are resistant to cephalosporins, but not carbapenems). Like the conclusions of the CDC’s report in MMWR and of the findings of both Carbonne *et al***[21]** (2010) and Alrabaa *et al*[20] (2013), Aumeran *et al*[21] (2010) further report that the outbreak’s strain “was finally isolated from one duodenoscope (*i.e.*, an ERCP endoscope).” Specifically, these authors report that: (1) ERCP endoscopes “can act as a reservoir” for ESBL-producing K. pneumoniae and other types of multi-drug resistant bacteria; (2) contamination of the ERCP endoscopes persisted “despite repeated disinfections”; (3) these ERCP endoscopes are “difficult to clean and disinfect” and are of a design that precludes detachment of their distal tip, making “mechanical removal of the distal debris in the elevator wire channel more difficult”; and (4) “appropriate mechanical flushing and cleaning with detergent of the raiser channel that contains the elevator wire is an essential step for these devices”**[21].**

Similarly, Bajolet *et al***[13]** (2013) reported an outbreak at a hospital in Reimes, France, in 2011, linked to a single gastroscope contaminated with ESBL-producing *P. aeruginosa*, which is yet a third type of gram-negative, multidrug-resistant superbug related to (but not) CRE*.* In addition to having identified some important breaches in the manual cleaning of the gastroscope, Bajolet *et al***[13]** (2013) report that a minor defect, namely, wear of adhesive at the gastroscope's distal sheath, “may have contributed to the development and persistence of bacterial biofilm in this case”. This report highlights the importance of, not only the potential contribution of the GI endoscope’s physical design to HAIs, but also the proper servicing, maintenance, and visual inspections of GI endoscopes to the prevention of patient-to-patient transmission of CRE. And, Naas *et al***[24]** (2010) reported an outbreak in France caused by a single contaminated side-viewing duodenoscope’s transmission of KPC-producing *K. pneumoniae*. To prevent infection, these authors recommend: (1) prompt reprocessing of the GI endoscope after its use – not as many as 24 hours later during which time patient debris may dry and harden on the endoscopes, becoming more difficult or remove during cleaning; (2) assuring thorough drying of the GI endoscope's internal channels; and (3) microbiologically sampling the GI endoscope several times a year, to evaluate its channels and other surfaces for bacterial contamination.

Like those published in the peer-reviewed medical literature, a number of reports recently filed in the FDA’s MAUDE database by hospitals and manufacturers of GI endoscopes and related medical equipment (but without identifying the medical facility by its name), as a regulatory requirement, provide important information into the causes of, risk factors for, and prevention of CRE transmissions during GI endoscopy**[36-39]** [The MAUDE database features medical device reports mandatorily submitted to the FDA by certain entities (*e.g.*, manufacturers and medical facilities) and voluntarily reported by health care professionals, patients and consumers]. These reports almost exclusively cite a contaminated ERCP endoscope as the likely cause of a confirmed infection or outbreak of CRE or their related superbugs following GI endoscopy. Several of these reports filed in 2012, 2013 and 2014 are listed in Table 4,including the report in the MAUDE database documenting Hospital X’s outbreak. (Outbreaks of CRE linked to contaminated GI endoscopes in the United States and identified in the MAUDE database were most common in 2014 and rarest in 2012, one reason for which may be that CRE and its related superbugs have only recently emerged). But, as with infections of carbapenem-susceptible bacteria linked to GI endoscopy, whether the actual incidence of CRE transmissions due to a contaminated GI endoscope is significantly higher than reported in the medical literature and the FDA’s MAUDE database, due to, for example, under-reporting, is unclear, although possible and suspected**[43]**.

In summary, several reports of infections and colonizations in the United States and Europe (often France, the reasons for which are unclear) due to a GI endoscope, most often to an ERCP endoscope, contaminated with CRE or a related superbug have been published during the past few years, both in the peer-reviewed medical literature and the FDA’s MAUDE database (Table 4). These reports frequently cite the physical design of the GI endoscope as a factor contributing to disease transmission, often adding that the ERCP endoscope’s “forceps elevator” or “elevator area” is difficult to clean and typically the surface of the endoscope contaminated with the outbreak’s superbug strain (Figure 1B), despite these investigations typically reporting that this surface was reprocessed**[20-22,25]**. In one instance (*i.e.*, Hospital X’s CRE outbreak), the replacement of automated high-level disinfection of the GI endoscope with EtO sterilization terminated the CRE outbreak**[25,31]**.For each of these reports, whether the outbreak’s strain of CRE or their related superbugs originated in the environment (*e.g*., contaminated water) or was patient-borne is typically not determined or clarified**[21]**.

***Transmission of CRE and related superbugs during other types of flexible endoscopic procedures***

A demonstrated public health threat both in the United States and globally, transmissions of CRE are not exclusive to GI endoscopy. Other types of flexible endoscopic procedures, including bronchoscopy and cystoscopy (as well as other types of medical procedures unrelated to flexible endoscopy), are also identified risk factors for infections (and predictors for colonizations) with CRE and related superbugs**[23,44-46]**.Indeed, some infection-control measures designed to prevent CRE transmission during GI endoscopy may also be employed during these other flexible endoscopic procedures, for the successful prevention of infection. For example, Koo *et al***[23]** (2012) discuss an outbreak of NDM-1 *K. pneumoniae* linked to contamination of the video camera head of urological instrumentation*.* Chang *et al***[44]** (2013) similarly report a CRE outbreak at a regional teaching hospital in southern Taiwan, finding an ureteroscope contaminated with ertapenem-resistant *E. cloacae* (a type of CRE) to be responsible for several UTIs. Chang *et al*[44]’s (2013) findings are not entirely surprising, since UTIs are the most common types of HAIs caused by CRE. Like Hospital X’s CRE outbreak, this outbreak in Taiwan was terminated only once the hospital used EtO sterilization to process the implicated ureteroscope**[9,25,44]**.

Sorin *et al***[45]** (2001) report that 18 patients were either colonized or infected with imipenem-resistant *P. aeruginosa* (IRPA), an infectious strain of bacteria that, while of the *Pseudomonadaceae,* not Enterobacteriaceae, family and therefore not CRE, is a related superbug that is resistant to carbapenems (Noted previously, imipenem is a type of carbapenem antibiotic). This outbreak was reportedly due to the improper connection of an automated reprocessing device to the bronchoscope’s suction channel, presumably precluding the endoscope’s effective reprocessing. Sorin *et al*[45]’s (2001) findings suggest that contaminated bronchoscopes, too, like GI endoscopes and urological equipment, pose a risk of transmission of multidrug-resistant gram-negative bacteria, like IRPA and CRE. Whether other types of GI endoscopes featuring an exposed elevator wire channel, such as those used during endoscopic ultrasonography (or, “EUS”), might also be difficult to clean and pose an increased risk of CRE transmission is unclear, but possible**[47]**.Based in part on a review of Sorin *et al***[45]**’s (2001) report, Muscarella (2004) found that environmental surfaces including tap water may, too, be reservoirs for antibiotic-resistant strains of gram-negative bacteria[46].

***High-level disinfection: Does it rapidly destroy CRE and related superbugs?***

An important question to address - in response to the CDC’s report in *MMWR* that Hospital X’s outbreak of CRE (and the CRE outbreak reported by Chang *et al***[44]**, 2013) seemingly stopped after this hospital replaced (automated) high-level disinfection of its ERCP endoscopes with EtO sterilization**[25]** - is whether high-level disinfection can indeed destroy CRE and their related superbugs (either *in vitro* or *in vivo*). A number of studies and published data address this concern. Aumeran *et al***[21]** (2010), for example, report that a peracetic acid-based high-level disinfectant (sold in Europe) was tested and verified to be “fully effective” against a multidrug-resistant strain of *K. pneumoniae.*Additionally, several intermediate-level disinfectants registered with the Environmental Protection Agency (EPA) in the United States are specifically labeled to destroy CRE within 1 or 2 min**[48,49].** Whereas intermediate-level disinfectants are tuberculocidal, high-level disinfectants are even more robust, being both tuberculocidal *and*, during longer exposure times, sporicidal. It is therefore reasonable to conclude that all high-level disinfectants cleared by the FDA destroy virtually every strain of CRE even more rapidly than intermediate-level disinfectants.

Moreover, not only gram-negative superbugs like CRE, but also such gram-positive superbugs as MRSA and VRE are reported to be no more resistant to intermediate-level disinfection (*i.e*., their destruction does not require a longer time of exposure to the disinfectant) than their antibiotic-*susceptible* counterparts, carbapenem-susceptible *Enterobacteriaceae,* “MSSA” and “VSE,” respectively**[48,49]**. While some of the published data are conflicting, other reports suggest that the development of antibiotic resistance by bacteria does not appear to be correlated with an increased resistance to disinfectants**[50,51]**. In short, published data suggest that: (1) high-level disinfection rapidly kills CRE and their related superbugs; (2) cleaning followed by high-level disinfection (and thorough drying and proper storage) of GI endoscopes, especially ERCP endoscopes, is sufficient and safe for the prevention of transmissions of all pathogenic microorganisms, including CRE**[30,32]**;and (3) EtO sterilization is not required to prevent CRE transmissions *via* a GI endoscope**[30]** (both the CDC’s report in *MMWR***[25]** and Chang *et al***[44]**’s [2013] report notwithstanding).

***The CDC’s, SGNA’s and ASGE’s recommendations for reprocessing GI endoscopes contaminated with CRE***

The CDC reported that Hospital X’s aforementioned outbreak of CRE in 2013 was terminated once the hospital replaced automated high-level disinfection of its ERCP endoscopes with EtO sterilization**[25,31]**.According to one hospital official, as a precaution, Hospital X “moved to (ethylene oxide) gas sterilization for these particular scopes, which exceeds the manufacturer’s recommended cleaning and disinfectant guidelines to ensure no other patients are at risk”**[29].**No matter, the CDC does not recommend the EtO sterilization of all ERCP endoscopes, stating in 2014 that: “At this time, CDC recommends facilities reprocess endoscopes as directed by the manufacturer; however, this is a focus of the ongoing assessments. CDC is not recommending a wholesale switch to sterilization; however, facilities should review their endoscope reprocessing practices to ensure all manufacturers' reprocessing recommendations are followed exactly. Any reprocessing recommendations, including sterilization with ethylene oxide (if recommended), would be validated by the manufacturer”**[30].**

Consistent with the CDC’s stance, the *Society for Gastroenterology Nurses and Associates* (SGNA) and the *American Society for Gastrointestinal Endoscopy* (ASGE) issued a joint statement in 2014, in response to Hospital X’s CRE outbreak the previous year. In that statement both organizations concluded that: “If ERCP-related transmission of CRE is suspected, reprocessing and preventative maintenance procedures for ERCP endoscopes should be evaluated in consultation with the manufacturer of the endoscope and automated endoscope reprocessor, if used”**[32]**. Their statement adds the following directive: “Please remember to follow the manufacturer’s safety and reprocessing instructions, and don’t hesitate to contact your manufacturer’s representative for any questions related to equipment reprocessing”**[32].**In short, neither ASGE nor SGNA recommends that current endoscope reprocessing practices be revised, upgraded or enhanced. These practices, which define the current standard of care, include high-level disinfection (preceded by manual cleaning) for the prevention of CRE transmissions during GI endoscopy and other flexible endoscopic procedures.

***Some unresolved issues associated with Hospital X’s CRE outbreak in 2013***

**Community-acquired CRE infections?** A number of issues surrounding Hospital X’s outbreak of CRE remain unresolved, including its precise cause(s). In addition to Hospital X’s 38 exposed patients who were found to be either colonized (*n* = 28) or infected (*n* = 10) with CRE following ERCP,the CDC reportedthat another 6 patients (44 patients, in total) were also similarly infected or colonized with CRE in northeastern Illinois (United States) between January and December, 2013**[25,31]**,causing this outbreak of CRE to be the largest in U.S. history, although none of these 6 other patients reportedly received care at Hospital X.Whether any of these 6 infected or colonized patients had been in direct or indirect contact with one or more of Hospital X’s 38 affected patients, demonstrating, possibly, community-associated transmission of CRE, is unclear.

**EtO sterilization:**As previously noted, the CDC reported (in *MMWR*) that no new cases of CRE transmissions due to a contaminated ERCP endoscope were identified once Hospital X replaced the automated high-level disinfection of its ERCP endoscopes (using an AER) with EtO sterilization**[25,29,31]**.Whether this low-temperature sterilization process is sufficiently robust to overcome, possibly, the hindrances that the ERCP endoscope's complex physical design reportedly poses to successful reprocessing, or that some other confounding factor altogether was responsible instead for stopping Hospital X’s CRE outbreak, requires more confirmatory data (No matter, EtO sterilization may be used by a healthcare facility as one of several “bundled” interventions concomitantly implemented to terminate a CRE outbreak. Circumspection is recommended, however, as no device that uses EtO gas has been cleared by the FDA with the specific intended use to sterilize ERCP endoscopes). Also previously noted, Bernie *et al*[9] (1983) recommended, and Chang *et al*[44] (2013) implemented, EtO sterilization to prevent transmission of the HBV via a GI endoscope and of CRE via a ureteroscope, respectively.The conclusion suggested by the CDC**[25]** that the ERCP endoscope's complex physical design - including that of its forceps elevator (Figure 1B) which presumably hindered reprocessing - was a primary contributor to, if not the cause of, Hospital X’s CRE outbreak also requires more confirmatory data.

**CRE-contaminated water?** Hospital X’s use of EtO sterilization for the apparent termination of its CRE outbreak in 2013 intriguingly raises another unresolved issue: that, possibly, a hitherto overlooked factor might have contributed to or caused this outbreak - namely, one that Muscarella (2010)**[2]** has previously discussed as a risk factor for other, similar instances of transmissions of multidrug-resistant bacteria during GI endoscopy: contaminated tap water. Because the CDC’s report in *MMWR* does not discuss whether Hospital X’s environmental surfaces, including its tap water or the AER’s rinse water, were microbiologically sampled for contamination with CRE**[25]**, there remains the possibility that the water supply (or another related moist or wet environmental surface, such as a sink) used by Hospital X to rinse its ERCP endoscope following high-level disinfection might have been contaminated with the outbreak’s strain of CRE (*i.e.,* NDM-1-producing E. coli).[CMS’s inspection report of Hospital X[31]raises the possibility, in addition to the two strains of CRE that the CDC recovered from one of Hospital X’s contaminated ERCP endoscope (*i.e.*, NDM-producing *E. coli* and KPC-producing *K. pneumonia*), that a third strain of CRE - namely, NDM-producing *K. pneumoniae* - might also have infected or colonized at least one patient [*i.e.*, “Patient #10”[31]] who underwent ERCP during the time of Hospital X’s outbreak and who subsequently expired] Indeed, contaminated rinse water used during endoscope reprocessing, coupled with inadequate drying of the ERCP endoscope’s internal channels after terminal water rinsing, is a commonly documented contributor to bacterial transmissions via contaminated GI endoscopes**[2,7,8,11,12]**. For certain, in addition to a human’s GI tract, water (and soil) is a documented reservoir of CRE**[2,44,45,51-54].** That another unrecognized factor altogether may have been the primary cause of Hospital X’s CRE outbreak also remains plausible.

**Faulty reprocessing?**According to the CMS’s aforementioned health inspection report published in 2014, in the aftermath of Hospital X’s CRE outbreak, the manufacturer of the implicated ERCP endoscope model asserts that Hospital X did not clean its ERCP endoscopes as their labeling instructs**[31]**. First, instead of it using the cleaning brushes specifically designed, validated and “highly recommended” (but not necessarily required) by the ERCP endoscope’s manufacturer, this inspection report states that Hospital X used another manufacturer’s brushes to clean its ERCP endoscopes (*i.e*., a claimed “off-label” practice). Second, this inspection report also indicates that Hospital X used an enzymatic detergent to clean the implicated ERCP endoscopes that had not been “approved” by the endoscope’s manufacturer and confirmed to be compatible with the materials used in the endoscope’s construction (*i.e.*, another claimed “off-label” practice). The extent to which Hospital X’s failure to use either the specific type of cleaning brushes or a detergent recommended or approved by the ERCP endoscope’s manufacturer, respectively, contributed to Hospital X’s CRE outbreak is unclear.

**Patient mortality linked to GI endoscopy:**Of Hospital X’s 38 patients who were exposed to the outbreak strain of CRE while undergoing ERCP in 2013, 28 patients became colonized and 10 infected, with two of these 10 infected patients subsequently dying**[31]**. Whether the outbreak’s strain of CRE was the primary cause of these deaths, only contributed to them in part, or incidental is subject to professional judgment and both clinical data and debate. No matter, the fact that two of Hospital X’s 10 CRE-infected patients died following their exposure to one of three contaminated ERCP endoscopes is an additional testament, not only to GI endoscopy now being a confirmed risk factor for CRE infection, but also to the importance of reprocessing every one of the GI endoscope’s potentially contaminated surfaces and areas following its use, lest the instrument remain contaminated and transmit CRE or their related superbugs.

**RECOMMENDATIONS AND GUIDANCE**

Several recommendations are provided to prevent transmissions of CRE and their related superbugs during GI endoscopy (and other types of flexible endoscopic procedures). For example, strict adherence to the cleaning instructions provided by the GI endoscope’s (or the AER’s) manufacturer, especially the instructions for brushing the area around, near and behind the forceps elevator located at the distal end of the ERCP endoscope (Figure 1B), is emphasized. More frequent monitoring of reprocessing staffers to verify the proper reprocessing of GI endoscopes, particularly ERCP endoscopes, is also recommended. High-level disinfection, whether achieved using a FDA-cleared aldehyde-based disinfectant or an oxizing agent, remains the recommended standard of care and can be expected to destroy CRE rapidly. Use of EtO sterilization for processing GI endoscopes, in lieu of manual or automated high-level disinfection, is neither contraindicated nor required (except, possibly, as part of an initial and “bundled” response to terminate a CRE outbreak)**[30]**. Enhanced surveillance designed to identify CRE infections and colonizations quickly and proactively, such as the screening of patients (*e.g.,* rectal or perianal swabbing to detect gastrointestinal carriage of CRE) upon admission, warrants consideration. A number of other interventions intended to prevent CRE transmission are provided below. Review of other published articles that provide additional guidance for the prevention of transmisson of all types of infectious agents during GI endoscopy is encouraged**[3-6,14,46,55-58]**.

***Transmission-based precautions***

Standard precautionsare important to the prevention of CRE transmissions in the GI endoscopic setting. For example: (1) practice proper hand-hygiene etiquette consistent with the CDC’s guidelines**[59]**;(2) don personal protective equipment (PPE), wearing gloves, gowns, and face mask, as needed**[15]**; and (3) in addition to high-level disinfecting (or sterilizing) GI endoscopes (and other *semi-critical* devices), sterilize reusable critical items, such as reusable biopsy forceps, and regularly clean and disinfect (using a low- or intermediate-level disinfectant) both non-critical devices, such as stethoscopes, and environment surfaces, such as countertops, as prescribed by the CDC’s guidelines (i.e., ideally, using an EPA-registered, hospital-grade disinfectant labeled to rapidly kill CRE for those surfaces potentially contaminated with these superbugs)**[60]**. Moreover, the prevention of CRE transmissions will also likely require the implementation of *Contact Precautions* for patients infected or colonized with CRE, cohorting these patients and the healthcare staff treating them as deemed necessary**[25]**.

***Endoscope reprocessing***

A number of recommended practices for the proper reprocessing of GI endoscopes that are based on this article’s findings are provided inTable 3. Recommended practices include placing emphasis on the cleaning and complete brushing (prior to high-level disinfection) of the area of the ERCP endoscope near, around and behind its forceps elevator (Figure 1B), as well as flushing this endoscope’s elevator wire channel (if it is exposed and unsealed) with detergent using a procedure validated for effectiveness. The use of cleaning accessories, including brushes and detergents, recommended and validated by the GI endoscope’s manufacturer may prove to be crucial.

***Other recommendations***

Efforts by healthcare professionals to educate themselves on the epidemiology of CRE and related superbugs; their modes of transmission; their common sources and reservoirs; and their mechanisms of resistance to carbapenems and other antibiotics are encouraged as part of a broad program to prevent CRE transmissions during GI endoscopy. Better stewardship and the reduced or restricted (and more judicious) use of antimicrobial drugs for the treatment of patients infected with CRE and their related superbugs is recommended as a corrective action to slow, if not to prevent, the development of antibiotic-resistant infections. And, of course, failure to adhere to strict aseptic techniques during the administration of IV medications used during GI endoscopy poses a significant risk of viral (and bacterial) transmissions**[57]**.

Attention by manufacturers of GI endoscopes to perform, in addition to performance testing and other regulatory requirements, enhanced risk assessments and other quality, safety and design-control strategies that assess the likelihood of CRE transmissions; evaluate the potential impact of these transmissions (which can be significant) on patient safety; mitigate the risk of these transmissions (and other patient harms) during GI endoscopy – for example, by enhancing endoscope designs to facilitate further more complete reprocessing; and, by updating the endoscope’s reprocessing manuals to provide even more detailed cleaning instructions using even better performing cleaning brushes and detergents); and validate the success of each corrective and preventive action employed to prevent these transmissions *via* a GI endoscope is encouraged. Indeed, because of the possibility that the FDA’s regulatory oversight of manufacturers of GI endoscopes and related instrumentation – like closer scrutiny, too, of the infection-control and endoscope-reprocessing practices of surveyed GI endoscopy departments by healthcare accrediting organizations and state health departments - may increase as a consequence of several recently disclosed CRE outbreaks (see text, *above*, and Table 4), it may prove prudent for both manufacturers and GI endoscopy departments alike to place enhanced focus on quality activities specifically designed to prevent CRE transmissions during GI endoscopy.

**CONCLUSION**

Not only are they an emerging public health threat (Table 2) both globally and in the Unites States, but this article identified GI endoscopy to be a risk factor for infection and colonization with CRE and their related superbugs (as well as with other types of antibiotic-resistant bacteria; antibiotic-susceptible bacteria, too; and other infectious agents, including viruses), with associated morbidity and mortality[33]. Strict adherence to infection control in the GI endoscopic setting is necessary to ensure patient safety and prevent disease transmission[33]. High-level disinfection is reported to be sufficient to prevent a GI endoscope from transmitting CRE and their related superbugs. Nonetheless, EtO sterilization may be employed prophylactically or once CRE transmissions have been confirmed (unless it is contraindicated by the GI endoscope’s manufacturer), although the effectiveness of this low-temperature sterilization process for the prevention of CRE transmission is based on clinical data and reports, not necessarily rigorous simulated-in use validation studies that have been reviewed by the FDA. Special attention is placed on healthcare staff assuring thorough cleaning of the ERCP endoscope (Figure 1B), especially the area around, behind and near its forceps elevator (and, if exposed, the flushing of its elevator wire channel with a detergent validated for effectiveness and materials’ compatibility). Additional recommendations are provided in Table 3. And, Table 4 lists a number of reports of outbreaks of CRE (or a related superbug) following GI endoscopy submitted to the FDA’s MAUDE database by manufacturers between 2012 and 2014.

**REFERENCES**

1 **Petersen BT**, Chennat J, Cohen J, Cotton PB, Greenwald DA, Kowalski TE, Krinsky ML, Park WG, Pike IM, Romagnuolo J, Rutala WA. Multisociety guideline on reprocessing flexible gastrointestinal endoscopes: 2011. *Gastrointest Endosc* 2011; **73**: 1075-1084 [PMID: 21628008 DOI: 10.1016/j.gie.2011.03.1183]

2 **Muscarella LF**. Investigation and prevention of infectious outbreaks during endoscopic retrograde cholangiopancreatography. *Endoscopy* 2010; **42**: 957-959 [PMID: 21072715 DOI: 10.1055/s-0030-1255871]

3 **Muscarella LF**. The study of a contaminated colonoscope. *Clin Gastroenterol Hepatol* 2010; **8**: 577-580.e1 [PMID: 20610350 DOI: 10.1016/j.cgh.2010.04.025]

4 **Nelson DB**, Muscarella LF. Current issues in endoscope reprocessing and infection control during gastrointestinal endoscopy. *World J Gastroenterol* 2006; **12**: 3953-3964 [PMID: 16810740]

5 **Muscarella LF**. Inconsistencies in endoscope-reprocessing and infection-control guidelines: the importance of endoscope drying. *Am J Gastroenterol* 2006; **101**: 2147-2154 [PMID: 16968511]

6 **Muscarella LF**. Recommendations for preventing hepatitis C virus infection: analysis of a Brooklyn endoscopy clinic's outbreak. *Infect Control Hosp Epidemiol* 2001; **22**: 669 [PMID: 11842983]

7 **Allen JI**, Allen MO, Olson MM, Gerding DN, Shanholtzer CJ, Meier PB, Vennes JA, Silvis SE. Pseudomonas infection of the biliary system resulting from use of a contaminated endoscope. *Gastroenterology* 1987; **92**: 759-763 [PMID: 3817396]

8 **Alvarado CJ**, Stolz SM, Maki DG. Nosocomial infections from contaminated endoscopes: a flawed automated endoscope washer. An investigation using molecular epidemiology. *Am J Med* 1991; **91**: 272S-280S [PMID: 1928177]

9 **Birnie GG**, Quigley EM, Clements GB, Follet EA, Watkinson G. Endoscopic transmission of hepatitis B virus. *Gut* 1983; **24**: 171-174 [PMID: 6852628]

10 **Bronowicki JP**, Venard V, Botté C, Monhoven N, Gastin I, Choné L, Hudziak H, Rihn B, Delanoë C, LeFaou A, Bigard MA, Gaucher P. Patient-to-patient transmission of hepatitis C virus during colonoscopy. *N Engl J Med* 1997; **337**: 237-240 [PMID: 9227929]

11 **Cryan EM**, Falkiner FR, Mulvihill TE, Keane CT, Keeling PW. Pseudomonas aeruginosa cross-infection following endoscopic retrograde cholangiopancreatography. *J Hosp Infect* 1984; **5**: 371-376 [PMID: 6085091]

12 **Struelens MJ**, Rost F, Deplano A, Maas A, Schwam V, Serruys E, Cremer M. Pseudomonas aeruginosa and Enterobacteriaceae bacteremia after biliary endoscopy: an outbreak investigation using DNA macrorestriction analysis. *Am J Med* 1993; **95**: 489-498 [PMID: 8238065]

13 **Bajolet O**, Ciocan D, Vallet C, de Champs C, Vernet-Garnier V, Guillard T, Brasme L, Thiefin G, Cadiot G, Bureau-Chalot F. Gastroscopy-associated transmission of extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa. *J Hosp Infect* 2013; **83**: 341-343 [PMID: 23337251 DOI: 10.1016/j.jhin.2012.10.016]

14 **Kovaleva J**, Peters FT, van der Mei HC, Degener JE. Transmission of infection by flexible gastrointestinal endoscopy and bronchoscopy. *Clin Microbiol Rev* 2013; **26**: 231-254 [PMID: 23554415 DOI: 10.1128/CMR.00085-12]

15 **Deas T**, Sinsel L. Ensuring patient safety and optimizing efficiency during gastrointestinal endoscopy. *AORN J* 2014; **99**: 396-406 [PMID: 24581646 DOI: 10.1016/j.aorn.2013.10.022]

16 **Centers for Disease Control and Prevention (CDC).** Vital signs: carbapenem-resistant Enterobacteriaceae. *MMWR Morb Mortal Wkly Rep* 2013; **62**: 165-170 [PMID: 23466435]

17 **Eisler P.** Deadly superbugs invade U.S. health care facilities. USA Today. 2013 March 6 [cited 2014 Augest 20]. Available from: http://www.usatoday.com/story/news/nation/2012/11/29/bacteria-deadly-hospital-infection/1727667/

18 **Mazzariol A**, Bošnjak Z, Ballarini P, Budimir A, Bedenić B, Kalenić S, Cornaglia G. NDM-1-producing Klebsiella pneumoniae, Croatia. *Emerg Infect Dis* 2012; **18**: 532-534 [PMID: 22377049 DOI: 10.3201/eid1803.1103890]

19 **Centers for Disease Control and Prevention (CDC).** Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. *MMWR Morb Mortal Wkly Rep* 2010; **59**: 750 [PMID: 20577157]

20 **Alrabaa SF**, Nguyen P, Sanderson R, Baluch A, Sandin RL, Kelker D, Karlapalem C, Thompson P, Sams K, Martin S, Montero J, Greene JN. Early identification and control of carbapenemase-producing Klebsiella pneumoniae, originating from contaminated endoscopic equipment. *Am J Infect Control* 2013; **41**: 562-564 [PMID: 23171594 DOI: 10.1016/j.ajic.2012.07.008]

21 **Aumeran C**, Poincloux L, Souweine B, Robin F, Laurichesse H, Baud O, Bommelaer G, Traoré O. Multidrug-resistant Klebsiella pneumoniae outbreak after endoscopic retrograde cholangiopancreatography. *Endoscopy* 2010; **42**: 895-899 [PMID: 20725887 DOI: 10.1055/s-0030-1255647]

22 **Carbonne A**, Thiolet JM, Fournier S, Fortineau N, Kassis-Chikhani N, Boytchev I, Aggoune M, Seguier JC, Senechal H, Tavolacci MP, Coignard B, Astagneau P, Jarlier V. Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009. *Euro Surveill* 2010; **15**: [PMID: 21144448]

23 **Koo VS**, O'Neill P, Elves A. Multidrug-resistant NDM-1 Klebsiella outbreak and infection control in endoscopic urology. *BJU Int* 2012; **110**: E922-E926 [PMID: 23107243 DOI: 10.1111/j.1464-410X.2012.11556.x]

24 **Naas T**, Cuzon G, Babics A, Fortineau N, Boytchev I, Gayral F, Nordmann P. Endoscopy-associated transmission of carbapenem-resistant Klebsiella pneumoniae producing KPC-2 beta-lactamase. *J Antimicrob Chemother* 2010; **65**: 1305-1306 [PMID: 20382724 DOI: 10.1093/jac/dkq117]

25 **Centers for Disease Control and Prevention (CDC).** Notes from the Field: New Delhi metallo-β-lactamase-producing Escherichia coli associated with endoscopic retrograde cholangiopancreatography - Illinois, 2013. *MMWR Morb Mortal Wkly Rep* 2014; **62**: 1051 [PMID: 24381080]

26 **McCoppin R**, Dizikes C. Superbug found at suburban hospital. The Chicago Tribune [updated 2014 January 10; cited 2014 August 20]. Available from: URL: http://articles.chicagotribune.com/2014-01-10/health/ct-hospital-bacteria-exposure-met-20140110\_1\_bacteria-superbug-cre

27 **Peterson E.** Lutheran General finds, stops bacteria source. The Daily Herald. 2013 December 27 [cited 2014 August 20]. Available from: http://www.dailyherald.com/article/20131227/news/712279757/

28 **Sfondeles T**. Largest outbreak of dangerous bacteria in U.S. tied to Park Ridge hospital. Chicago Sun Times. 2014 January 5 [cited 2014 August 20]. Available from: http://www.suntimes.com/news/metro/24748492-418/largest-outbreak-of-dangerous-bacteria-in-us-tied-to-park-ridge-hospital.html#.U\_SOjGOS\_Kc Accessed: August 20, 2014

29 **Johnson CK.** Lutheran General upgrades scope cleaning after ‘superbug’ outbreak. Chicago Sun Times. 2014 January 3 [cited 2014 August 20]. Available from: URL: http://www.suntimes.com/news/metro/24742098-418/lutheran-general-upgrades-scope-cleaning-after-superbug-outbreak.html#.U\_SO-2OS\_Kc

30 **Kelly JC**. CDC Confirms superbug transmission via endoscopy. Medscape Medical News. 2014 January 03 [cited 2014 August 20]. Available from: http: //www.medscape.com/viewarticle/818650

31 **Centers for Medicare and Medicaid Services (CMS)**. Advocate Lutheran General Hospital. Statement of Deficiencies and Plan of Correction. OMB No. 0938-0391. 2014 January 16 [cited 2014 August 20]. Available from: http: //www.hospitalinspections.org/report/3413

32 ASGE, SGNA. CDC report outlines NDM-producing CRE infection transmission via ERCP. 2014 January 8 [cited 2014 August 20]. Available from: http://www.sgna.org/Portals/0/ASGE-SGNA\_CDC-ERCPreponse\_1-8-14.pdf

33 **Gastmeier P**, Vonberg RP. Klebsiella spp. in endoscopy-associated infections: we may only be seeing the tip of the iceberg. *Infection* 2014; **42**: 15-21 [PMID: 24166131 DOI: 10.1007/s15010-013-0544-6]

34 **Centers for Disease Control and Prevention.** Antibiotic resistance threats in the United States 2013; p.1-114. (Reference No.: CS239559-B) [cited 2014 August 20]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf

35 **Falagas ME**, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. *Emerg Infect Dis* 2014; **20**: 1170-1175 [PMID: 24959688 DOI: 10.3201/eid2007.121004]

36 **Food and Drug Administration. Incident report.** MAUDE database. [updated 2014 March 06; cited 2014 August 20].Report number: 2518897-2014-00001. Available from: URL:

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/Detail.CFM?MDRFOI\_\_ID=3795541

37 **Food and Drug Administration.** Incident report. MAUDE database. [updated 2014 March 04; cited 2014 August 20]. Report number: MW5029305. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi\_\_id=2999629

38 **Food and Drug Administration.** Incident report. MAUDE database. [updated 2014 January 16; cited 2014 August 20]. Report number: 2951238-2014-00027. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/detail.cfm?mdrfoi\_\_id=3608977

39 **Food and Drug Administration.** MAUDE database. [updated 2014 January 16; cited 2014 August 20]. Report number: MW5033987. Available from:

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/Detail.CFM?MDRFOI\_\_ID=3596905

40 **Jovcic B**, Lepsanovic Z, Suljagic V, Rackov G, Begovic J, Topisirovic L, Kojic M. Emergence of NDM-1 metallo-β-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. *Antimicrob Agents Chemother* 2011; **55**: 3929-3931 [PMID: 21646490 DOI: 10.1128/AAC.00226-11]

41 **Delaware Health and Social Services.** Division of Public Health. Health Alert: First confirmed U.S. case of NDM-producing carbapenem-resistant Pseudomonas aeruginosa. Delaware Health Alert Network #324. [updated 2014 May 5; cited 2014 August 20]. Available from: http: //dhss.delaware.gov/dph/php/alerts/dhan324.html

42 Update: detection of a verona integron-encoded metallo-beta-lactamase in Klebsiella pneumoniae - United States, 2010. *MMWR Morb Mortal Wkly Rep* 2010; **59**: 1212 [PMID: 20864922]

43 **Dirlam Langlay AM**, Ofstead CL, Mueller NJ, Tosh PK, Baron TH, Wetzler HP. Reported gastrointestinal endoscope reprocessing lapses: the tip of the iceberg. *Am J Infect Control* 2013; **41**: 1188-1194 [PMID: 24021660 DOI: 10.1016/j.ajic.2013.04.022]

44 **Chang CL**, Su LH, Lu CM, Tai FT, Huang YC, Chang KK. Outbreak of ertapenem-resistant Enterobacter cloacae urinary tract infections due to a contaminated ureteroscope. *J Hosp Infect* 2013; **85**: 118-124 [PMID: 23954065 DOI: 10.1016/j.jhin.2013.06.010]

45 **Sorin M**, Segal-Maurer S, Mariano N, Urban C, Combest A, Rahal JJ. Nosocomial transmission of imipenem-resistant Pseudomonas aeruginosa following bronchoscopy associated with improper connection to the Steris System 1 processor. *Infect Control Hosp Epidemiol* 2001; **22**: 409-413 [PMID: 11583207]

46 **Muscarella LF**. Contribution of tap water and environmental surfaces to nosocomial transmission of antibiotic-resistant Pseudomonas aeruginosa. *Infect Control Hosp Epidemiol* 2004; **25**: 342-345 [PMID: 15108733]

47 **Olson J.** HCMC alerts patients: Medical instrument wasn’t fully sterilized. Twin Cities.com [updated 2010 June 22; cited 2014 August 20]. Available from: http://www.twincities.com/minneapolis/ci\_15353711

48 Clorox Healthcare. Clorox Healthcare Bleach Germicidal Cleaners. Testing results. [cited 2014 August 20]. Available from: http://www.cloroxprofessional.com/products/clorox-healthcare-bleach-germicidal-cleaners/efficacy-claims/

49 PURE Bioscience, Inc. Technical report and efficacy statement. PURE Hard Surface spray disinfectant. [updated October 2011; cited 2014 August 20]. Available from:

http://www.nilodor.com/Member/nilodor/Images/ImageGallery/flyers/pure\_hard\_surface\_disinfectant.pdf

50 **Mavri A**, Kurincic M, Smole Mozina S. The prevalence of antibiotic and biocide resistance among Campylobacter coli and Campylobacter jejuni from different sources. *Food Technol Biotechnol* 2012; **50:** 371–376. Available from:

http: //hrcak.srce.hr/file/129400 Accessed: August 20, 2014.

51 **Rutala WA**, Stiegel MM, Sarubbi FA, Weber DJ. Susceptibility of antibiotic-susceptible and antibiotic-resistant hospital bacteria to disinfectants. *Infect Control Hosp Epidemiol* 1997; **18**: 417-421 [PMID: 9181398]

52 **Kotsanas D**, Wijesooriya WR, Korman TM, Gillespie EE, Wright L, Snook K, Williams N, Bell JM, Li HY, Stuart RL. "Down the drain": carbapenem-resistant bacteria in intensive care unit patients and handwashing sinks. *Med J Aust* 2013; **198**: 267-269 [PMID: 23496403]

53 **Starlander G**, Melhus Å. Minor outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in an intensive care unit due to a contaminated sink. *J Hosp Infect* 2012; **82**: 122-124 [PMID: 22871394 DOI: 10.1016/j.jhin.2012.07.004]

54 **Walsh TR**, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. *Lancet Infect Dis* 2011; **11**: 355-362 [PMID: 21478057 DOI: 10.1016/S1473-3099(11)70059-7]

55 **Muscarella LF**. The risk of disease transmission associated with inadequate disinfection of gastrointestinal endoscopes. *J Hosp Infect* 2006; **63**: 345-347 [PMID: 16713021]

56 **Muscarella LF**. Dear Los Angeles Times: the risk of disease transmission during gastrointestinal endoscopy. *Gastroenterol Nurs* ; **27**: 271-278 [PMID: 15632761]

57 **Muscarella LF**. Infection control and its application to the administration of intravenous medications during gastrointestinal endoscopy. *Am J Infect Control* 2004; **32**: 282-286 [PMID: 15292893]

58 **Muscarella LF**. Instrument design and cross-infection. *AORN J* 1998; **67**: 552-53, 556 [PMID: 9541700]

59 **Boyce JM**, Pittet D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. *MMWR Recomm Rep* 2002; **51**: 1-45, quiz CE1-4 [PMID: 12418624]

60 **Sehulster L**, Chinn RY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). *MMWR Recomm Rep* 2003; **52**: 1-42 [PMID: 12836624]

61 **Akyüz N**, Keskin M, Akyolcu N, Cavdar İ, Özbaş A, Ayoğlu T, Balık E, Bulut T. How and how much do endoscopy professionals protect themselves against infection? *Int J Surg* 2014; **12**: 720-724 [PMID: 24859352 DOI: 10.1016/j.ijsu.2014.05.065]

62 **Food and Drug Administration**. Incident report. MAUDE database. Report number: 2518897-2013-00005 [Internet]. [updated 2013 October 28; cited 2014 August 20].

Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi\_\_id=3457417

63 FUJIFILM Medical Systems U.S.A., Inc. – Endoscopy Division. Reprocessing summary and guide for Fujinon/Fujifilm flexible GI endoscopes. Reference code: FRG-120323 [Internet]. [cited 2014 August 20]; p.1-7. Available from: http://www.sgna.org/Portals/0/InfectionPrevention/Manufacturer/38\_Fujifilm Reprocessing Guide 3 23 12.pdf

64 **Muscarella LF**. Application of environmental sampling to flexible endoscope reprocessing: the importance of monitoring the rinse water. *Infect Control Hosp Epidemiol* 2002; **23**: 285-289 [PMID: 12026158]

65 **Muscarella LF**. Tap Water Used for Irrigation during GI Endoscopy: A Recommendation and Assessment of the Infection Risk. Discussions in Infection Control [An on-line blog] Available from: URL: http://endoscopereprocessing.com/2014/05/asge-guidelines-safety-gi-endoscopy-2014/ Accessed: August 20, 2014.

66 **Muscarella LF**. Disinfecting endoscopes immediately before the first patient of the day. *AORN J* 2001; **73**: 1159-1163 [PMID: 11409235]

67 **Hookey L**, Armstrong D, Enns R, Matlow A, Singh H, Love J. Summary of guidelines for infection prevention and control for flexible gastrointestinal endoscopy. *Can J Gastroenterol* 2013; **27**: 347-350 [PMID: 23781518]

68 Association of periOperative Registered Nurses. Perioperative Standards and Recommended Practices. Recommended practices for cleaning and processing flexible endoscopes and endoscope accessories. In: Perioperative Standards and Recommended Practices. Denver, CO: AORN, Inc; 2013: 473-484

**P-Reviewer:** Bugaj AM, Koulaouzidis A **S-Editor:** Ji FF **L-Editor: E-Editor:**

****



The elevator forceps in its “half-opened, half-closed” position.

**Figure 1 Displayed a FujiFilm 530-series duodenoscope and forceps elevator.** A: Displayed is a FujiFilm 530-series duodenoscope, also known as an ERCP endoscope. Also displayed is an endoscopic accessory (colored white with green and red strips), which was passed through the endoscope’s working (or instrument) channel and is seen exiting the endoscope’s distal tip). B: Displayed is the forceps elevator of a FujiFilm duodenoscope. This forceps elevator is also visible in Figure 1A.

 

**Figure 2 Displayed is the β-lactam ring’s four-membered (*i.e.*, a square) chemical structure.**

  

†

**A**: The core chemical structure **B**: The core chemical structure of penicillin antibiotics of carbapenem antibiotics

**Figure 3 Displayed are the core chemical structures of two different types of β-lactam antibiotics: A penicillin (A) and a carbapenem (B).** Both antibiotics feature the four-membered β-lactam ring. A: The core chemical structure of penicillin antibiotics; B. The core chemical structure of carbapenem antibiotics.**†**The “R” in either diagram denotes a distinct side chain that is attached to the molecule’s core).

**Table 1 Several questions that this article answers**

1. What is a “superbug”?
2. What are carbapenem-resistant *Enterobacteriaceae*, or “CRE,” and their related superbugs?
3. What are carbapenem-producing *Enterobacteriaceae*, or “CPE”?
4. What important mechanism can cause CRE to become resistant to carbapenem antibiotics?
5. What is a “carbapenemase” enzyme?
6. What is a “β-lactam antibiotic” and a “β-lactam ring”?
7. What are ESBL-producing *Enterobacteriaceae* and how do they differ from CRE?
8. What types of infections do CRE cause?
9. By what three mechanisms may *Enterobacteriaceae* acquire the genetic coding necessary to produce carbapenemases and become carbapenem-resistant?
10. Prior to the emergence of CRE, what types of infectious agents have been historically transmitted during GI endoscopy?
11. Is GI endoscopy a risk factor for CRE transmissions?
12. What are some of the details and possible causes of the well-publicized CRE outbreak following ERCP performed by “Hospital X” in the mid-west (United States) that has recently raised public concerns about the risk of transmission of CRE during GI endoscopy?
13. What are some of the details of other CRE outbreaks that similarly have been linked to GI endoscopy since this superbug’s emergence and have been published either in the medical literature or the FDA’s MAUDE database?
14. Is high-level disinfection (whether automated or performed manually) of GI endoscopes sufficiently robust to prevent CRE transmissions? Or, is ethylene oxide gas (EtO) sterilization of GI endoscopes required to prevent CRE transmissions?
15. What do professional organizations including the CDC, FDA, SGNA, and ASGE currently recommend for reprocessing GI endoscopes potentially contaminated with CRE?
16. What are some important recommendations that healthcare professionals may follow to minimize the risk of CRE transmission during GI endoscopy?

**Table 2 Reasons why the recent emergence of carbapenem-resistant *Enterobacteriaceae* and their related superbugs is a serious public-health concern**

1. While HAIs caused by CRE are relatively uncommon, their incidence both in the United States. and globally is increasing, posing a growing public health threat**[16,19,25,32]**
2. Strains of *Enterobacteriaceae* that are responsible for HAIs are becoming CRE at an alarming rate
3. Infections of the bacterial strains that have emerged as CRE were once treatable with carbapenems, but are no longer, even though these antibiotics have been reserved by clinicians as a “last resort” or “last line” of defense for treating patients infected with multidrug-resistant bacteria
4. CRE’s resistance to carbapenems significantly limits the number of available treatment options
5. Those very few antibiotics that remain effective for treating CRE infections are generally undesirable because, among some other limitations, they can be nephrotoxic
6. Some strains of CRE are *pan*-resistant (meaning they cannot be treated using *any* type of antibiotic)
7. The mortality rate of infections caused by CRE and related superbugs is relatively high (compared to carbapenem-susceptible *Enterobacteriaceae*), causing the death of as many as 50% of patients with a bloodstream infection of CRE
8. Not only are the number of patient deaths attributed to CRE infection (from all causes, not just bacteremia) significant, both in the United States and globally, but also the rate of death among patients with CRE infections (primarily of the bloodstream) has been reported to be as much as 2 times higher than that of patients infected with carbapenem-susceptible *Enterobacteriaceae* (CSE)**[35]**
9. The genetic code that confers the antibiotic resistance of CRE and their related superbugs can be shared or exchanged with other bacteria of the same, or of even of a different, species (*i.e.*, “gene swapping”)
10. CRE and related superbugs are highly transmissible in the healthcare setting (and have the potential to spread in the community too)

**CRE:** Carbapenem-resistant *Enterobacteriaceae.*

**Table 3 Recommended practices for the effective reprocessing of gastrointestinal endoscopes**

1 Reprocess the GI endoscope promptly after the endoscopic procedure in accordance with its manufacturer’s step-by-step set of instructions

(1) As required, supplement these instructions with the recommendations of published infection-control guidelines

(2) Always reprocess the GI endoscope’s air/water channels (Also, always reprocess the GI endoscope’s suction and air/water valves and other accessories)

(3) Before its reprocessing, visually examine the GI endoscope, especially its distal sheath, for excessive wear and tear, having it servicing when required

(4) Practice *Standard Precautions* when reprocessing GI endoscopes (As required, also employ *Contact Precautions* to prevent CRE transmission)

2 Place emphasis on cleaning and brushing (prior to high-level disinfection) the area near, around and behind the ERCP endoscope’s forceps elevator (Figure 1B)

(1) Ensure that, if it is exposed, the ERCP endoscope’s elevator wire channel, which houses the cable that controls and angulates this forceps elevator, is thoroughly flushed with a detergent solution

(2) Routinely train and evaluate the knowledge of reprocessing staffers

(3) Periodically audit reprocessing staffers’ practices to verify the proper cleaning and brushing of all models of GI endoscopes, especially the ERCP endoscopes**[61]**

(4) Use cleaning brushes and detergents that have been validated, recommended, and/or “approved” for use by the GI endoscope’s manufacturer**[31,62,63]**

(5) Manually “leak test” the GI endoscope prior to its cleaning in accordance with its manufacturer’s instructions (unless otherwise instructed by the automated endoscope reprocessor’s [or, AER’s] manufacturer, if the AER is equipped with an automated leak tester)

3 Routinely monitor (*i.e.*, at least once a day, if not more often) the concentration of the high-level disinfectant to ensure its effectiveness. Record the results in a log book or use an electronic format that permits archiving and documentation retreival

(1) In addition to its concentration, verify and record for each processed GI endoscope that the high-level disinfectant’s immersion time and temperature are appropriate

4 Use bacteria-free (or sterile) water to rinse the GI endoscope following its high-level disinfection

(1) Compliance with this instruction may require: (A) proper maintenance and replacement of a water filtration system, if one is used; and (B) routine monitoring of the rinse water to confirm its lack of bacteria**[64]**

5 Consider using sterile water in the water bottle for lens cleaning and irrigation during GI endoscopy, especially during ERCP**[15,65]**

6 Terminally dry all of the GI endoscope’s internal channels (including the ERCP elevator wire channel, if it is exposed) using 70% alcohol and forced air**[5,66]**

7 Store the GI endoscope with its insertion tube hanging freely and vertically in a clean, dry, and well-ventilated area or cabinet**[66,67]**

(1) Consider reprocessing the GI endoscope again before its reuse if it has been stored for more than 5 d**[68]**. Reprocessing ERCP endoscopes before each use may be advisable

8 If using an AER, ensure that it is performing properly; has been validated for the effective reprocessing of each GI endoscope in inventory; has been serviced and maintained as required; and that its internal surfaces and components are being routinely self-disinfected as instructed by its manufacturer

CRE: Carbapenem-resistant *Enterobacteriaceae;* GI: Gastrointestinal.

**Table 4 A number of reports of outbreaks of carbapenem-resistant *Enterobacteriaceae* (or a related superbug) following gastrointestinal endoscopy that were filed in the Food and Drug Administration’s *MAUDE* database between 2012 and 2014 by manufacturers of gastrointestinal endoscopes and related medical equipment**

**Reports filed in 2014:**

(1) Food and Drug Administration. Report date: May 2, 2014. Report number: 2951238-2014-00225. (Infections or colonizations of patients following ERCP with an extended β-lactamase [ESBL] strain of *E. coli* strain. Also refer to Report number: 2951238-2014-00004)

(2) Food and Drug Administration. Report date: March 7, 2014. Report number: 2518897-2014-00001[36]. (Infections or colonizations of patients following ERCP with CRE)

(3) Food and Drug Administration. Report date: January, 28, 2014. Report number: 2951238-2014-00027[38].(Infections or colonizations of patients following ERCP with CRE)

(4) Food and Drug Administration. Report date: January 16, 2014. Report number: MW5033987[39].(Infections or colonizations of patients following ERCP with CRE)

(5) Food and Drug Administration. Report date: May 27, 2014. Report number: MW5036408. (One patient infected or colonized with CRE following ERCP)

**Reports filed in 2013:**

(1) Food and Drug Administration. Report date: March 4, 2013. Report number: MW5029305[37]. (Infections or colonizations of patients following ERCP with CRE)

(2) Food and Drug Administration. Report date: September 30, 2013, and October 28, 2013. Report number: 2518897-2013-00005. (Also refer to Report number: 2523209-2013-00013). *Note:* This report was presumably filed by Hospital X documenting its CRE outbreak identified between January and September, 2013

**Reports filed in 2012:**

(1) Food and Drug Administration. Report date: September 25, 2012. Report number: 8010047-2012-00404. (Infections or colonizations of patients following ERCP with a multidrug-resistant *E. coli*)

(2) Food and Drug Administration. Report date: November 21, 2012. Report number: 8010047-2012-00454. (Possible infections or colonizations of patients following ERCP with *E. coli;* the bacterial strain is not necessarily resistant to antibiotics; and this incident may be a pseudo-outbreak, not true infections or colonizations)

These reports, which do not identify the medical facility by name, associate a contaminated ERCP endoscope with a confirmed patient infection or colonization, or an outbreak of CRE or a related superbug. (Some of these reports are included in this article’s reference section. The listed reports for each year, below, may not be inclusive of every filed report). CRE: Carbapenem-resistant *Enterobacteriaceae;* GI: Gastrointestinal.